Publication: History and perspective of immunotherapy for pythiosis
Issued Date
2021-10-01
Resource Type
ISSN
2076393X
Other identifier(s)
2-s2.0-85116320234
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines. Vol.9, No.10 (2021)
Suggested Citation
Hanna Yolanda, Theerapong Krajaejun History and perspective of immunotherapy for pythiosis. Vaccines. Vol.9, No.10 (2021). doi:10.3390/vaccines9101080 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77216
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
History and perspective of immunotherapy for pythiosis
Author(s)
Other Contributor(s)
Abstract
The fungus-like microorganism Pythium insidiosum causes pythiosis, a life-threatening infectious disease increasingly reported worldwide. Antimicrobial drugs are ineffective. Radical surgery is an essential treatment. Pythiosis can resume post-surgically. Immunotherapy using P. insidiosum antigens (PIA) has emerged as an alternative treatment. This review aims at providing up-to-date information of the immunotherapeutic PIA, with the focus on its history, preparation, clinical application, outcome, mechanism, and recent advances, in order to promote the proper use and future development of this treatment modality. P. insidiosum crude extract is the primary source of immunotherapeutic antigens. Based on 967 documented human and animal (mainly horses) pythiosis cases, PIA immunotherapy reduced disease morbidity and mortality. Concerning clinical outcomes, 19.4% of PIA-immunized human patients succumbed to vascular pythiosis instead of 41.0% in unimmunized cases. PIA immunotherapy may not provide an advantage in a local P. insidiosum infection of the eye. Both PIA-immunized and unimmunized horses with pythiosis showed a similar survival rate of ~70%, however, demands for surgical intervention were much lesser in the immunized cases (22.8% vs. 75.2%). The proposed PIA action involves switching the non-protective T-helper-2 to protective T-helper-1 mediated immunity. By exploring the available P. insidiosum genome data, synthetic peptides, recombinant proteins, and nucleic acids are potential sources of the immunotherapeutic antigens worth investigating. The PIA therapeutic property needs improvement for a better prognosis of pythiosis patients.